BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12102166)

  • 1. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
    Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL; Kerbauy J; Oliveira JS
    Acta Oncol; 2002; 41(2):192-6. PubMed ID: 12102166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
    Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
    Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
    Milligan MG; Bigger E; Abramson JS; Sohani AR; Zola M; Kayembe MKA; Medhin H; Suneja G; Lockman S; Chabner BA; Dryden-Peterson SL
    J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
    Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
    J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
    Mwanda WO; Orem J; Fu P; Banura C; Kakembo J; Onyango CA; Ness A; Reynolds S; Johnson JL; Subbiah V; Bako J; Wabinga H; Abdallah FK; Meyerson HJ; Whalen CC; Lederman MM; Black J; Ayers LW; Katongole-Mbidde E; Remick SC
    J Clin Oncol; 2009 Jul; 27(21):3480-8. PubMed ID: 19470940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
    Diamond C; Taylor TH; Im T; Anton-Culver H
    Leuk Lymphoma; 2006 Sep; 47(9):1822-9. PubMed ID: 17064995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy.
    Gérard L; Galicier L; Boulanger E; Quint L; Lebrette MG; Mortier E; Meignin V; Oksenhendler E
    AIDS; 2003 Jan; 17(1):81-7. PubMed ID: 12478072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
    Antinori A; Cingolani A; Alba L; Ammassari A; Serraino D; Ciancio BC; Palmieri F; De Luca A; Larocca LM; Ruco L; Ippolito G; Cauda R
    AIDS; 2001 Aug; 15(12):1483-91. PubMed ID: 11504980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
    Sharma A; Bajpai J; Raina V; Mohanti BK
    Indian J Cancer; 2010; 47(1):35-9. PubMed ID: 20071788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
    Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
    AIDS Res Hum Retroviruses; 2002 Mar; 18(4):237-42. PubMed ID: 11860669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
    Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
    Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
    Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
    Tirelli U; Spina M; Jaeger U; Nigra E; Blanc PL; Liberati AM; Benci A; Sparano JA
    Recent Results Cancer Res; 2002; 159():149-53. PubMed ID: 11785839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
    Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
    Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.